Actavis sues FDA over generic Celebrex
April 28 (Reuters) - Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.
The move follows a similar lawsuit announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex. (Reporting by Susan Kelly in Chicago; Editing by Bernard Orr)
© Thomson Reuters 2017 All rights reserved.